A Chinese scientist reviewing laboratory equipment

Research news

This section contains news items that were not issued as a press release.

Tuesday, 12 June 2012
Five additional pharmaceutical companies have joined a National Institutes of Health’s effort to help scientists research promising new treatments for patients. The programme is focused on discovering new therapeutic uses for existing molecules – a collaboration AstraZeneca already joined earlier this year.
Monday, 11 June 2012
AstraZeneca and Nobel Media bring Nobel Laureate Bruce Beutler to Boston On June 11-12, 2012, as part of a worldwide initiative between AstraZeneca, a global innovation-driven biopharmaceutical company, and Nobel Media AB, the company responsible for media rights for the Nobel Prize, students, researchers and staff at the Whitehead Institute for Biomedical Research and AstraZeneca’s Boston based Research and Development facility will have the opportunity to meet and learn from 2011 Nobel Laureate in Physiology or Medicine Dr Bruce Beutler.
Friday, 8 June 2012
Cancer Research UK launches trial of experimental drug combination for advanced stomach and oesophageal cancer Cancer Research UK’s Drug Development Office (DDO) has joined forces with academia and industry to open a clinical trial that will test an experimental drug from AstraZeneca called AZD4547 in combination with standard chemotherapy to treat a group of patients with advanced stomach or oesophageal cancer.
Thursday, 24 May 2012
Innovative public-private collaboration launches to tackle antibiotic research New €224m (£180m) funding to enable development of antibiotics for bacterial infections and drive unprecedented information sharing
Thursday, 3 May 2012
NIH launches collaborative program with industry and researchers Scientists will gain access to select compounds from Pfizer, AstraZeneca, and Lilly
Tuesday, 1 May 2012
Axerion Therapeutics and AstraZeneca to Develop and Commercialize a Biologic Approach for the Treatment of Alzheimer’s Disease Axerion Therapeutics, Inc., a private Connecticut-based biotechnology company, and MedImmune the global biologics arm of AstraZeneca, announced today that they have entered into a research collaboration and sublicense arrangement to develop and commercialize a biologic approach for the treatment of Alzheimer's disease.
Monday, 23 April 2012
AstraZeneca to acquire Ardea Biosciences for $1 billion (net of existing cash) including lead product lesinurad in Phase III development for gout   AstraZeneca and Ardea Biosciences, Inc. (Ardea) today announced that they have entered into a definitive merger agreement, pursuant to which AstraZeneca will acquire Ardea, a San Diego, California-based biotechnology company focused on the development of small-molecule therapeutics.  Ardea’s clinically most advanced product candidate, lesinurad (formerly known as RDEA594), is currently in Phase III development as a potential treatment for the chronic management of hyperuricaemia in patients with gout.
Monday, 16 April 2012
Conformetrix and AstraZeneca sign collaborative agreement Conformetrix Ltd, a leader in optimising drug discovery and design, and AstraZeneca announced today that they have signed a research collaboration agreement under which Conformetrix’s proprietary NMR-based technology will be applied across AstraZeneca’s pre-clinical therapeutic pipeline to enhance lead discovery and hit identification.
Thursday, 12 April 2012
AstraZeneca and Liverpool School of Tropical Medicine combine resources in the fight against Neglected Tropical Diseases AstraZeneca and the Liverpool School of Tropical Medicine announce a research agreement aimed at finding new medicines to treat river blindness and lymphatic filariasis, which are neglected tropical diseases (NTDs) that affect millions of people.
Thursday, 12 April 2012
AstraZeneca and DNDi to Collaborate on Drug Screening for Neglected Tropical Diseases AstraZeneca and the Drugs for Neglected Diseases initiative (DNDi) announce an agreement to collaborate on drug-compound screening for leishmaniasis, Chagas disease, and sleeping sickness, three neglected tropical diseases (NTDs) which together affect nearly 10 million people worldwide.